Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

1.

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.

Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy-Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE.

Am J Hematol. 2015 Jun 1. doi: 10.1002/ajh.24034. [Epub ahead of print]

PMID:
26040495
2.

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ.

Invest New Drugs. 2015 May 2. [Epub ahead of print]

PMID:
25933833
3.

Management of advanced-phase chronic myeloid leukemia.

DeFilipp Z, Khoury HJ.

Curr Hematol Malig Rep. 2015 Jun;10(2):173-81. doi: 10.1007/s11899-015-0249-2.

PMID:
25929768
4.

CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Suessmuth Y, Mukherjee R, Watkins B, Koura DT, Finstermeier K, Desmarais C, Stempora L, Horan JT, Langston A, Qayed M, Khoury HJ, Grizzle A, Cheeseman JA, Conger JA, Robertson J, Garrett A, Kirk AD, Waller EK, Blazar BR, Mehta AK, Robins HS, Kean LS.

Blood. 2015 Jun 18;125(25):3835-50. doi: 10.1182/blood-2015-03-631853. Epub 2015 Apr 7.

PMID:
25852054
5.

Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.

Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z, Boggon TJ, Jin P, Yi H, Wright ER, Duong D, Seyfried NT, Egnatchik R, DeBerardinis RJ, Magliocca KR, He C, Arellano ML, Khoury HJ, Shin DM, Khuri FR, Kang S.

Cancer Cell. 2015 Feb 9;27(2):257-70. doi: 10.1016/j.ccell.2014.12.006.

PMID:
25670081
6.

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R.

Clin Cancer Res. 2015 Mar 1;21(5):985-94. doi: 10.1158/1078-0432.CCR-14-1765. Epub 2014 Dec 5.

PMID:
25480830
7.

Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?

El Rassi F, Bergsagel JD, Arellano M, Gaddh M, Jillella A, Kota V, Heffner LT, Winton EF, Khoury HJ.

Cancer. 2015 Mar 15;121(6):872-5. doi: 10.1002/cncr.29142. Epub 2014 Nov 11.

PMID:
25387987
8.

Updated product label allows home administration of omacetaxine mepesuccinate.

Shen AQ, Munteanu M, Khoury HJ.

Oncologist. 2014 Nov;19(11):e14. doi: 10.1634/theoncologist.2014-0230. Epub 2014 Oct 3. No abstract available.

9.

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR.

Sci Transl Med. 2014 Sep 3;6(252):252ra121. doi: 10.1126/scitranslmed.3009073.

10.

Disposable platform provides visual and color-based point-of-care anemia self-testing.

Tyburski EA, Gillespie SE, Stoy WA, Mannino RG, Weiss AJ, Siu AF, Bulloch RH, Thota K, Cardenas A, Session W, Khoury HJ, O'Connor S, Bunting ST, Boudreaux J, Forest CR, Gaddh M, Leong T, Lyon LA, Lam WA.

J Clin Invest. 2014 Oct;124(10):4387-94. doi: 10.1172/JCI76666. Epub 2014 Aug 26.

11.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-42. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

PMID:
25132497
12.

Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect.

Fan J, Kang HB, Shan C, Elf S, Lin R, Xie J, Gu TL, Aguiar M, Lonning S, Chung TW, Arellano M, Khoury HJ, Shin DM, Khuri FR, Boggon TJ, Kang S, Chen J.

J Biol Chem. 2014 Sep 19;289(38):26533-41. doi: 10.1074/jbc.M114.593970. Epub 2014 Aug 7.

PMID:
25104357
13.

Incidence and geographic distribution of adult acute leukemia in the state of Georgia.

El Rassi F, Ward KC, Flowers CR, Heffner LT, Waller EK, Winton EF, Vaughn J, Hill BG, Langston A, Nooka A, Arellano M, Khoury HJ.

South Med J. 2014 Aug;107(8):497-500. doi: 10.14423/SMJ.0000000000000146.

PMID:
25084186
14.

Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.

Shan C, Elf S, Ji Q, Kang HB, Zhou L, Hitosugi T, Jin L, Lin R, Zhang L, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J.

Mol Cell. 2014 Aug 21;55(4):552-65. doi: 10.1016/j.molcel.2014.06.020. Epub 2014 Jul 17.

PMID:
25042803
15.

Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth.

Shan C, Kang HB, Elf S, Xie J, Gu TL, Aguiar M, Lonning S, Hitosugi T, Chung TW, Arellano M, Khoury HJ, Shin DM, Khuri FR, Boggon TJ, Fan J.

J Biol Chem. 2014 Aug 1;289(31):21413-22. doi: 10.1074/jbc.M114.581124. Epub 2014 Jun 24.

PMID:
24962578
16.

Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia.

Hill BG, Shen AQ, El Rassi F, Khoury HJ.

J Clin Oncol. 2014 Jun 16. pii: JCO.2013.50.1221. [Epub ahead of print] No abstract available.

PMID:
24934776
17.

Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.

Khoury HJ, Bixby DL.

Leuk Lymphoma. 2015 Mar;56(3):568-76. doi: 10.3109/10428194.2014.918969. Epub 2014 Jul 23.

PMID:
24884315
18.

Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Hill BG, Kota VK, Khoury HJ.

Expert Rev Anticancer Ther. 2014 Jul;14(7):765-70. doi: 10.1586/14737140.2014.924400. Epub 2014 May 30.

PMID:
24875651
19.

Bosutinib treatment for Philadelphia chromosome-positive leukemias.

Bethelmie-Bryan B, Lord K, Holloway S, Khoury HJ.

Future Oncol. 2014 Feb;10(2):179-85. doi: 10.2217/fon.13.268.

PMID:
24490604
20.

Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.

Shen AQ, Wilson NM, Gleason SL, Khoury HJ.

Ther Adv Hematol. 2014 Feb;5(1):13-7. doi: 10.1177/2040620713510481. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk